Drug Class:
antipsychotics

PharmGKB contains no dosing guidelines for this drug class. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug class. To report a drug label with PGx, click here.

Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA ABCB1 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *5 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *6 N/A N/A N/A
No VIP available No VIP available VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available No VIP available VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available CA VA
rs10042486 13855688C>T, 1791G>A, 63261329C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs1010978 10414T>C, 129479460T>C, 13747170T>C, 160+211T>C, 169+211T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available No Clinical Annotations available VA
rs10490624 118862492T>C, 369+1595T>C, 8611155T>C
T > C
Intronic
No VIP available CA VA
rs10501087 27610108T>C, 27670108T>C, 305+8556T>C, 374+8556T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs1065852 100C>T, 21917263G>A, 42526694G>A, 5190C>T, CYP2D6:100C>T, Pro34Ser, part of CYP2D6*4 and CYP2D6*10
G > A
Missense
Pro34Ser
No VIP available CA No Variant Annotations available
rs1079598 -31-870T>C, 113296274A>G, 16858690A>G, 54728T>C
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs10807344 299-1064C>T, 46565635C>T, 46625635C>T
C > T
Intronic
No VIP available CA VA
rs11030104 -128-4044T>C, -138-2698T>C, -21-4385T>C, 226-4385T>C, 25-4385T>C, 27624517A>G, 27684517A>G, 4-4385T>C, 585+3742A>G, 64089T>C, 654+3742A>G, 67-4385T>C
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs11123469 -2073T>C, 118844183T>C, 8592846T>C
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs1128503 1236T>C, 167964T>C, 25043506A>G, 87550285A>G, ABCB1 1236C>T, ABCB1*8, ABCB1: c.1236T>C, ABCB1:1236C>T, ABCB1:1236T>C, Gly412=, Gly412Gly, mRNA 1654T>C, p.Gly412Gly
A > G
Not Available
Gly412Gly
No VIP available No Clinical Annotations available VA
rs1137101 177266A>G, 36030431A>G, 66058513A>G, 668A>G, Gln223Arg
A > G
Missense
Gln223Arg
No VIP available CA VA
rs1344706 185778428A>C, 256-19902A>C, 35987846A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs1379357 12639725G>C, 24781579G>C
G > C
Not Available
No VIP available CA VA
rs1414334 114138144C>G, 324594C>G, 456-3008C>G, 551-3008C>G, 570476C>G
C > G
Intronic
No VIP available No Clinical Annotations available VA
rs1457266 -1455A>G, 12627998A>G, 24769852A>G, 3579A>G
A > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs17047764 118868582G>C, 8617245G>C
G > C
Not Available
No VIP available No Clinical Annotations available VA
rs17587100 118838410A>C, 8587073A>C
A > C
Not Available
No VIP available CA VA
rs17782313 5641961T>C, 57851097T>C
T > C
Not Available
No VIP available CA VA
rs1799732 -487_-486insC, 113346252_113346253insG, 16908668_16908669insG, 4749_4750insC, DRD2: -141C Ins/Del
- > G
5' Flanking
VIP No Clinical Annotations available No Variant Annotations available
rs1799752 16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 26840042_26840043insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, 61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, ACE D/I
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
Intronic
No VIP available No Clinical Annotations available VA
rs1799983 11291734T>G, 12965T>G, 150696111T>G, 894T>G, Asp298Glu, NOS3:894G>T
T > G
Missense
Asp298Glu
No VIP available CA VA
rs1800497 113270828G>A, 16833244G>A, 17316G>A, 2137G>A, 32806C>T, DRD2 Taq1A, DRD2:32806C>T, DRD2:Taq1A, DRD2:Taq1A A1, DRD2:TaqIA allele, Glu713Lys, Taq1A
G > A
Missense
Glu713Lys
No VIP available CA VA
rs1801133 11856378G>A, 14783C>T, 665C>T, 677C>T, 7861110G>A, A222V, Ala222Val, C677T, MTHFR: c.677C>T, MTHFR:667C>T, p.A222V
G > A
Missense
Ala222Val
No VIP available No Clinical Annotations available VA
rs1805128 21483551C>T, 253G>A, 35821680C>T, 66934G>A, Asp85Asn, KCNE1:Asp85Asn
C > T
Missense
Asp85Asn
No VIP available No Clinical Annotations available VA
rs1990761 13207121G>A, 162997703G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs2032582 186947T>A, 186947T>G, 25193461A>C, 25193461A>T, 2677A, 2677G, 2677T, 2677T>A, 2677T>G, 3095G>T/A, 87160618A>C, 87160618A>T, 893 Ala, 893 Ser, 893 Thr, ABCB1*7, ABCB1: 2677G>T/A, ABCB1: 2677T/A>G, ABCB1: A893S, ABCB1: G2677T/A, ABCB1: c.2677G>T/A, ABCB1:2677G>A/T, ABCB1:2677G>T/A, ABCB1:A893T, Ala893Ser/Thr, MDR1, MDR1 G2677T/A, Ser893Ala, Ser893Thr, mRNA 3095G>T/A, p.Ala893Ser/Thr
A > C
A > T
Missense
Ser893Ala
Ser893Thr
No VIP available CA VA
rs2061051 271-51145G>A, 27520811G>A, 309383G>A, 3955958G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs2067482 1341C>T, 46346767G>A, 46406767G>A, Thr447=
G > A
Synonymous
Thr447Thr
No VIP available CA VA
rs2069514 (-2964)G>A, 28338G>A, 3860G>A, 45828777G>A, 75038220G>A, CYP1A2*1C
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs2070744 -51-762C>T, -786, -813C>T, 11285702C>T, 150690079C>T, 6933C>T, NOS3 -786T>C, NOS3:, T>C, eNOS -786T>C
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs2235800 129498836T>A, 13766546T>A, 29790T>A, 710+110T>A, 719+110T>A
T > A
Intronic
No VIP available No Clinical Annotations available VA
rs2239483 129477451A>G, 13745161A>G, 67-1705A>G, 76-1705A>G, 8405A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs2270450 *458C>T, *489C>T, *684C>T, 46584875C>T, 46644875C>T
C > T
3' UTR
No VIP available CA VA
rs2445142 22225743G>C, 43008C>G, 64-2940C>G, 8905831G>C
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs2485914 246220746T>C, 355-127507A>G, 39738525T>C, 532-127507A>G
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs25531 -1936A>G, 28564346T>C, 3301340T>C, 3609A>G
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs35859249 373C>T, 37904089C>T, 5063451C>T, Arg125Trp
C > T
Missense
Arg125Trp
No VIP available No Clinical Annotations available VA
rs3757241 1826A>G, 225T>C, 46563698T>C, 46623698T>C, Ala75=
T > C
Synonymous
Ala75Ala
No VIP available No Clinical Annotations available VA
rs3761656 13220653T>G, 163011235T>G
T > G
Not Available
No VIP available No Clinical Annotations available VA
rs3813928 -1088G>A, -995, -997G>A, 113818282G>A, 250614G>A, 4732G>A, HTR2C c.-995G>A
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs3813929 -759, -759C>T, -850C>T, 113818520C>T, 250852C>T, 4970C>T, HTR2C:, HTR2C: -759C/T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs41368446 13207531T>G, 162998113T>G
T > G
Not Available
No VIP available CA VA
rs4606 *446C>G, 192781172C>G, 44269814C>G, 8004C>G
C > G
3' UTR
No VIP available No Clinical Annotations available VA
rs4633 -1041C>T, 186C>T, 19950235C>T, 25973C>T, 3102385C>T, 36C>T, COMT: His62His, His12=, His62=
C > T
5' Flanking
His62His
rs4680 1-5G>A, 19951271G>A, 27009G>A, 3103421G>A, 322G>A, 472G>A, COMP: Val158Met, COMT:Val108Met, Val108Met, Val158Met
G > A
5' Flanking
Val158Met
No VIP available CA VA
rs5030655 -1098delA, -1563delA, -951delA, -988delA, 23419520delA, 277delT, 353-140delT, 40+3506delA, 42129084delA, 454delT, 51411delA, 51425delA, 5908delT, CYP2D6*6, CYP2D6:1707 del T, Trp152Glyfs, Trp93Glyfs, part of CYP2D6*6
A > -
Not Available
Trp152Gly
No VIP available No Clinical Annotations available VA
rs518147 -697G>C, -788G>C, 113818582G>C, 250914G>C, 5032G>C, HTR2C: -697G/C
C > G
5' UTR
No VIP available No Clinical Annotations available VA
rs586773 19002405A>T, 2280T>A, 73696610A>T
A > T
Not Available
No VIP available No Clinical Annotations available VA
rs591758 19003855G>C, 73698060G>C, 830C>G
G > C
Not Available
No VIP available No Clinical Annotations available VA
rs5977250 129506392T>C, 13774102T>C, 37346T>C, 928-491T>C, 937-491T>C
T > C
Intronic
No VIP available CA VA
rs6265 196G>A, 220G>A, 241G>A, 27619916C>T, 27679916C>T, 283G>A, 434C>T, 442G>A, 503C>T, 68690G>A, BDNF:Val66Met, Val148Met, Val66Met, Val74Met, Val81Met, Val95Met
C > T
Missense
Val66Met
No VIP available CA No Variant Annotations available
rs6277 113283459G>A, 16845875G>A, 67543C>T, 870C>T, 957C>T, C957T, DRD2: C957T, DRD2:1035C>T, DRD2:1122C>T, DRD2:957C>T, Pro290=, Pro319=
G > A
Synonymous
Pro290Pro
No VIP available CA VA
rs6311 -1438, -510G>A, -998G>A, 28451478C>T, 4692G>A, 47471478C>T, G>A, HTR2A c.-1438G>A, HTR2A:, HTR2A: -1438G/A, HTR2A:-1438G>A
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs6313 102C>T, 160+869C>T, 28449940G>A, 47469940G>A, 6230C>T, HTR2A:102C>T, HTR2A:T102C, Ser34=
G > A
Intronic
Ser34Ser
No VIP available No Clinical Annotations available VA
rs6318 113965735G>C, 152185G>C, 398067G>C, 68G>C, Cys23Ser, HTR2C:23Ser, HTR2C:Cys23Ser
C > G
Missense
Cys23Ser
No VIP available No Clinical Annotations available VA
rs649446 -2336G>A, 19001640C>T, 3045G>A, 73695845C>T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs655717 14675T>C, 18990010A>G, 73684215A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs659366 -1245G>A, 19000549C>T, 4136G>A, 73694754C>T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs660339 164C>T, 18994899G>A, 73689104G>A, 9786C>T, Ala55Val
G > A
Missense
Ala55Val
No VIP available No Clinical Annotations available VA
rs668514 19012309C>T, 73706514C>T, 813G>A
C > T
Not Available
No VIP available CA VA
rs6977820 14667643T>C, 154072020T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs7295250 2716943T>C, 2776943T>C, 4584+995T>C, 4590+995T>C, 4614+995T>C, 4623+995T>C, 4674+995T>C, 4683+995T>C, 4689+995T>C, 4707+995T>C, 4767+995T>C, 701992T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs7566605 118836025C>G, 8584688C>G
C > G
Not Available
rs762551 -9-154C>A, 32035C>A, 45832474C>A, 75041917C>A, CYP1A2*1F, CYP1A2:734C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs7799039 127878783G>A, 2453G>A, 65911626G>A, LEP: -2548G/A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs806374 -63-2264A>G, -64+63A>G, 26977154T>C, 88857320T>C
T > C
Intronic
No VIP available CA VA
rs878949 22227091T>C, 41660A>G, 64-4288A>G, 8907179T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs9395206 46578422T>A, 46638422T>A, 704+1892T>A, 798-441T>A
T > A
Intronic
No VIP available No Clinical Annotations available VA
rs951436 14521984A>C, 163033342A>C
A > C
Not Available
No VIP available CA No Variant Annotations available
rs951439 14522333C>T, 163033691C>T, 296C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs9852 *68C>T, 38139024C>T, 5298386C>T
C > T
3' UTR
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to antipsychotics: 110

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics. 2014. Brandl Eva J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia. Schizophrenia research. 2013. Scarr Elizabeth, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophrenia research. 2013. Zhang Jian-Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013. Severino Giovanni, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Human psychopharmacology. 2013. Brandl Eva J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain. Journal of clinical psychopharmacology. 2013. Czerwensky Fabian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics. 2012. Mas Sergi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic testing and molecular biomarkers. 2012. Müller Daniel J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics. 2012. Vijayan Neetha N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia. Pharmacogenomics. 2012. Kuzman Martina Rojnic, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European archives of psychiatry and clinical neuroscience. 2012. Crisafulli Concetta, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. European archives of psychiatry and clinical neuroscience. 2012. Mössner Rainald, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia. The pharmacogenomics journal. 2012. Lott S A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. The pharmacogenomics journal. 2012. Chowdhury N I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuro endocrinology letters. 2012. Barteček Richard, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes. Circulation. Cardiovascular genetics. 2011. Kääb Stefan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics. 2011. Risselada Arne J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics. 2011. Zhang Xiang Rong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. The pharmacogenomics journal. 2011. Tanaka S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. The pharmacogenomics journal. 2011. Greenbaum L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine. The pharmacogenomics journal. 2011. Ono S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics. 2011. Gregoor Jochem G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics. 2011. Hill Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. International journal of clinical pharmacy. 2011. Wilffert Bob, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of an UCP4 (SLC25A27) haplotype with ultra-resistant schizophrenia. Pharmacogenomics. 2011. Mouaffak Fayçal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. The pharmacogenomics journal. 2011. Tiwari A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette Syndrome. Pharmacogenomics. 2010. Liao Isaac H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of antipsychotic-induced QTc interval prolongation. The pharmacogenomics journal. 2010. Aberg K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and genomics. 2010. Lencz Todd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. The pharmacogenomics journal. 2010. Liou Y-J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: dopamine receptor D2. Pharmacogenetics and genomics. 2010. Mi Huaiyu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. The pharmacogenomics journal. 2010. Risselada A J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The pharmacogenomics journal. 2010. Müller D J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Higher serum caffeine in smokers with schizophrenia compared to smoking controls. Drug and alcohol dependence. 2010. Gandhi Kunal K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. The American journal of psychiatry. 2010. Zhang Jian-Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenetics and genomics. 2010. Hong Chen-Jee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Horstmann Sonja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Human psychopharmacology. 2010. Tiwari Arun K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010. Lohoff Falk W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry research. 2010. Vázquez-Bourgon Javier, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. The pharmacogenomics journal. 2010. Liu Y-R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. The pharmacogenomics journal. 2009. Gassó P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenetics and genomics. 2009. Schuhmacher Anna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting age-specific dosing of antipsychotics. Clinical pharmacology and therapeutics. 2009. Uchida H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics. 2009. Calarge Chadi A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. The pharmacogenomics journal. 2009. Greenbaum L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Journal of psychiatric research. 2009. Shen Yu-Chih, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?. Molecular psychiatry. 2009. Le Hellard S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics. 2009. Gupta Meenal, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. Journal of clinical psychopharmacology. 2009. Mulder Hans, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. The pharmacogenomics journal. 2009. Popp J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of psychiatric research. 2008. Alenius Malin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Model-based gene selection shows engrailed 1 is associated with antipsychotic response. Pharmacogenetics and genomics. 2008. Webb Bradley Todd, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clinical and experimental pharmacology & physiology. 2008. Crescenti Anna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and genomics. 2008. Kohlrausch Fabiana B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenetics and genomics. 2008. Xu Ming-Qing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular psychiatry. 2008. Bakker P R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. American journal of human genetics. 2008. Mill Jonathan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese population. Nagoya journal of medical science. 2008. Ji Xiaofei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 phenotype prediction from genotype: which system is the best?. Clinical pharmacology and therapeutics. 2008. Kirchheiner J. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biological psychiatry. 2008. Campbell Daniel B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophrenia research. 2008. de Leon Jose, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophrenia research. 2008. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. The pharmacogenomics journal. 2007. Molero P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007. Xing Qinghe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. The pharmacogenomics journal. 2007. Tiwari A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. The pharmacogenomics journal. 2007. Mulder H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Molecular psychiatry. 2007. Zai C C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA and cell biology. 2007. Boke Omer, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. Journal of clinical psychopharmacology. 2007. Mulder Hans, et al. PubMed
Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2007. Tay Joshua K X, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. The pharmacogenomics journal. 2007. Theisen F M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007. Strous Rael D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
100 years and counting: prospects for defeating Alzheimer's disease. Science (New York, N.Y.). 2006. Roberson Erik D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
RGS4 genotype is not associated with antipsychotic medication response in schizophrenia. Journal of neural transmission (Vienna, Austria : 1996). 2006. Kampman O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics. Journal of clinical psychopharmacology. 2006. Nolan Karen A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert review of molecular diagnostics. 2006. de Leon Jose. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta pharmacologica Sinica. 2006. Fu Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenetics and genomics. 2006. Liou Ying-Jay, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. The American journal of psychiatry. 2006. Lencz Todd, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. The pharmacogenomics journal. 2006. Davies M A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 2005. Hwang Rudi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neuroscience letters. 2005. Wu Shengnan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenetics and genomics. 2005. Patsopoulos Nikolaos A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. The pharmacogenomics journal. 2005. Tiwari A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological psychiatry. 2004. Weickert Thomas W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. The American journal of psychiatry. 2004. Bertolino Alessandro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. The British journal of psychiatry : the journal of mental science. 2004. Young Ross McD, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics. 2004. Anttila Sami, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Therapeutic drug monitoring. 2004. Baumann P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. Journal of clinical psychopharmacology. 2003. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2003. Inada Toshiya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2003. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy. 2002. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. American journal of medical genetics. 2001. Schulze T G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics. 2001. Suzuki A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Molecular psychiatry. 2000. Basile V S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Molecular psychiatry. 2000. Kaiser R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1999. Basile V S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. International clinical psychopharmacology. 1999. Naranjo C A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. Journal of psychiatry & neuroscience : JPN. 1999. Joober R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 1998. Arranz M J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry research. 1998. Ohara K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Molecular psychiatry. 1997. Steen V M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Dopamine D2 receptors in signal transduction and behavior. Critical reviews in neurobiology. 1997. Picetti R, et al. PubMed

Clinical Trials

These are trials that mention antipsychotics and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.